Alzheimer’s Agitation Non-Antipsychotic Drug Therapy Market to Grow at 14.3% CAGR

The Business Research Company’s Alzheimer’s Agitation Non-Antipsychotic Drug Therapy Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, September 15, 2026 /EINPresswire.com/ — The market for Alzheimer’s agitation non-antipsychotic drug therapies is gaining significant attention due to the increasing need for safer and more effective treatment options for behavioral symptoms associated with Alzheimer’s disease. As the global population ages and awareness of dementia-related challenges grows, this segment is poised for robust expansion. Below, we explore the current market size, key growth drivers, regional dynamics, and upcoming trends shaping this important healthcare field.

Alzheimer’s Agitation Non-Antipsychotic Drug Therapy Market Size and Growth Outlook
The Alzheimer’s agitation non-antipsychotic drug therapy market has experienced rapid growth in recent years. It is projected to rise from $5.09 billion in 2025 to $5.85 billion in 2026, representing a compound annual growth rate (CAGR) of 14.7%. This expansion during the historical period has been driven by a rising prevalence of Alzheimer’s disease worldwide, an aging global population, increased awareness of behavioral symptoms in dementia care, enhanced neurological research initiatives, and growing concerns about the adverse effects linked to antipsychotic drugs.

Download a free sample of the alzheimer’s agitation non-antipsychotic drug therapy market report:
https://www.thebusinessresearchcompany.com/sample_request?id=14976650&type=smp&name=Alzheimer%27s%20Agitation%20Non-Antipsychotic%20Drug%20Therapy%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=paid&utm_campaign=Sep_PR

Looking ahead, the market is expected to continue its strong upward trajectory, reaching an estimated $9.98 billion by 2030 with a CAGR of 14.3%. Growth in the forecast period will be supported by increased investments in neurodegenerative disease drug development, a rising demand for precision medicine approaches, more clinical trials focused on novel neurobehavioral therapies, the expansion of home-based dementia care services, and stronger regulatory backing for safer treatment options. Emerging trends include the development of safer alternatives to antipsychotics, heightened emphasis on targeted management of neurobehavioral symptoms, broader adoption of multimodal therapeutic strategies for agitation, ongoing research into neurotransmitter pathway modulation, and an increase in clinical trials for innovative central nervous system therapies.

Understanding Alzheimer’s Agitation Non-Antipsychotic Drug Therapies
These therapies involve pharmacological treatments specifically designed to manage agitation, aggression, and related behavioral symptoms in Alzheimer’s patients without utilizing antipsychotic medications. The approach centers on modulating neurotransmitter systems and neurobiological pathways that influence mood, behavior, and cognition to improve symptom control. The goal is to offer safer options that reduce risks commonly associated with antipsychotics, such as sedation, cognitive decline, and cardiovascular complications.

View the full alzheimer’s agitation non-antipsychotic drug therapy market report:
https://www.thebusinessresearchcompany.com/report/alzheimers-agitation-non-antipsychotic-drug-therapy-market-report?utm_source=EINPresswire&utm_medium=paid&utm_campaign=Sep_PR

Key Factors Propelling the Alzheimer’s Agitation Non-Antipsychotic Drug Therapy Market
One of the primary growth drivers is the rising global prevalence of Alzheimer’s disease, a progressive neurodegenerative disorder that impairs memory, thinking, and behavior due to brain cell damage. Increased life expectancy has resulted in a growing elderly population, which in turn raises the number of individuals at risk for Alzheimer’s disease. As agitation and other behavioral symptoms are common in Alzheimer’s patients, non-antipsychotic drug therapies provide critical management solutions that improve quality of life and long-term care outcomes for this expanding patient base. For example, in December 2025, the Australian Government reported that around 25,000 people were living with dementia in Australia, including approximately 266,000 women and 159,000 men—equivalent to roughly 16 cases per 1,000 Australians.

Research and Development Investments Supporting Market Expansion
Another significant factor driving market growth is the increasing financial commitment to research and development. Governments, pharmaceutical companies, and academic institutions are allocating substantial resources to discover, develop, and clinically test new therapeutic agents for managing agitation in Alzheimer’s patients without relying on antipsychotics. The growing global burden of Alzheimer’s disease, fueled by an aging population, has heightened urgency for effective treatment options. This influx of funding accelerates the identification and validation of innovative drug candidates, broadening the therapeutic pipeline. For instance, data from the US National Center for Science and Engineering Statistics (NCSES) shows that research and development expenditures in the United States increased from $892 billion in 2022 to $940 billion in 2023, a rise of $48 billion.

Regional Outlook: Fastest Growing Markets in Alzheimer’s Agitation Non-Antipsychotic Drug Therapy
In 2025, North America held the largest share of the Alzheimer’s agitation non-antipsychotic drug therapy market. Looking forward, the Asia-Pacific region is anticipated to experience the fastest growth during the forecast period. The market analysis encompasses regions such as Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a comprehensive global perspective on emerging trends and opportunities.

Our latest 2026 market reports provide expanded strategic and visual intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, together with updated graphics and tables.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info

The Business Research Company – www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

Media gallery